184.20EUR+0.11%Mkt Cap: 8.90B $P/E: 83.26Today
Financière de Tubize SA holds a stake in UCB, a biopharmaceutical company in Belgium. It focuses on the discovery and development of treatments for patients suffering from diseases affecting immune or central nervous sys…
Industry Peers
Biotechnology$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$60.19BUSDP/E 39.1
$45.16BUSDP/E 19.2
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.17BUSDP/E 26.2
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
$12.59BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
LLe Soleil | ||
 Financière de Tubize (ENXTBR:TUB) After Half Year Earnings Is The Stock Now Too Pricey Recent earnings update and what it means for Financière de Tubize stock Financière de Tubize (ENXTBR:TUB) recently reported half year 2026 net income of €100.76 million compared with €95.57 million a year earlier, drawing fresh attention to how the holding company’s earnings feed into its current valuation. See our latest analysis for Financière de Tubize. The latest half year earnings have come at a time when Financière de Tubize’s share price has been under pressure, with the 30-day share... | ||
DDHnet | ||
LLa Libre.be | ||